| アブストラクト | BACKGROUND: Medications aimed at inhibiting the renin-angiotensin system (RAS) have been used extensively for preventing cardiovascular and renal complications in patients with diabetes, but data that compare their clinical effectiveness are limited. We aimed to compare the effects of classes of RAS blockers on cardiovascular and renal outcomes in adults with diabetes. METHODS AND FINDINGS: Eligible trials were identified by electronic searches in PubMed/MEDLINE and the Cochrane Database of Systematic Reviews (1 January 2004 to 17 July 2014). Interventions of interest were angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and direct renin (DR) inhibitors. The primary endpoints were cardiovascular mortality, myocardial infarction, and stroke-singly and as a composite endpoint, major cardiovascular outcome-and end-stage renal disease [ESRD], doubling of serum creatinine, and all-cause mortality-singly and as a composite endpoint, progression of renal disease. Secondary endpoints were angina pectoris and hospitalization for heart failure. In all, 71 trials (103,120 participants), with a total of 14 different regimens, were pooled using network meta-analyses. When compared with ACE inhibitor, no other RAS blocker used in monotherapy and/or combination was associated with a significant reduction in major cardiovascular outcomes: ARB (odds ratio [OR] 1.02; 95% credible interval [CrI] 0.90-1.18), ACE inhibitor plus ARB (0.97; 95% CrI 0.79-1.19), DR inhibitor plus ACE inhibitor (1.32; 95% CrI 0.96-1.81), and DR inhibitor plus ARB (1.00; 95% CrI 0.73-1.38). For the risk of progression of renal disease, no significant differences were detected between ACE inhibitor and each of the remaining therapies: ARB (OR 1.10; 95% CrI 0.90-1.40), ACE inhibitor plus ARB (0.97; 95% CrI 0.72-1.29), DR inhibitor plus ACE inhibitor (0.99; 95% CrI 0.65-1.57), and DR inhibitor plus ARB (1.18; 95% CrI 0.78-1.84). No significant differences were showed between ACE inhibitors and ARBs with respect to all-cause mortality, cardiovascular mortality, myocardial infarction, stroke, angina pectoris, hospitalization for heart failure, ESRD, or doubling serum creatinine. Findings were limited by the clinical and methodological heterogeneity of the included studies. Potential inconsistency was identified in network meta-analyses of stroke and angina pectoris, limiting the conclusiveness of findings for these single endpoints. CONCLUSIONS: In adults with diabetes, comparisons of different RAS blockers showed similar effects of ACE inhibitors and ARBs on major cardiovascular and renal outcomes. Compared with monotherapies, the combination of an ACE inhibitor and an ARB failed to provide significant benefits on major outcomes. Clinicians should discuss the balance between benefits, costs, and potential harms with individual diabetes patients before starting treatment. REVIEW REGISTRATION: PROSPERO CRD42014014404. |
|---|
| ジャーナル名 | PLoS medicine |
|---|
| Pubmed追加日 | 2016/3/10 |
|---|
| 投稿者 | Catala-Lopez, Ferran; Macias Saint-Gerons, Diego; Gonzalez-Bermejo, Diana; Rosano, Giuseppe M; Davis, Barry R; Ridao, Manuel; Zaragoza, Abel; Montero-Corominas, Dolores; Tobias, Aurelio; de la Fuente-Honrubia, Cesar; Tabares-Seisdedos, Rafael; Hutton, Brian |
|---|
| 組織名 | Department of Medicine, University of Valencia/INCLIVA Health Research Institute,;Valencia, Spain.;Division of Pharmacoepidemiology and Pharmacovigilance, Spanish Agency of;Medicines and Medical Devices (AEMPS), Madrid, Spain.;Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa,;Ontario, Canada.;Centro de Investigacion Biomedica en Red de Salud Mental (CIBERSAM), Instituto de;Salud Carlos III, Madrid, Spain.;Centre for Clinical and Basic Research, Department of Medical Sciences, Istituto;di Ricovero e Cura a Carattere Scientifico San Raffaele Pisana, Rome, Italy.;The University of Texas School of Public Health, Houston, Texas, United States of;America.;Instituto Aragones de Ciencias de la Salud, Red de Investigacion en Servicios de;Salud en Enfermedades Cronicas (REDISSEC), Zaragoza, Spain.;Fundacion para el Fomento de la Investigacion Sanitaria y Biomedica de la;Comunitat Valenciana (FISABIO-Salud Publica), Valencia, Spain.;Spanish Council for Scientific Research (CSIC), Barcelona, Spain.;Area of Budgetary Stability, Ministry of Finance and Public Administrations,;Madrid, Spain.;School of Epidemiology, Public Health and Preventive Medicine, Faculty of;Medicine, University of Ottawa, Ottawa, Ontario, Canada. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/26954482/ |
|---|
